These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19493069)

  • 1. Wild-card patent extensions as a means to incentivize research and development of antibiotics.
    Sonderholm J
    J Law Med Ethics; 2009; 37(2):240-6. PubMed ID: 19493069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Commentary: innovation policy for a new era.
    Kapczynski A
    J Law Med Ethics; 2009; 37(2):264-8. PubMed ID: 19493071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction: pharmaceutical innovation: law & the public's health.
    Outterson K
    J Law Med Ethics; 2009; 37(2):173-5. PubMed ID: 19493064
    [No Abstract]   [Full Text] [Related]  

  • 4. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
    Spellberg B; Miller LG; Kuo MN; Bradley J; Scheld WM; Edwards JE
    Infection; 2007 Jun; 35(3):167-74. PubMed ID: 17565458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diseases endemic in developing countries: how to incentivize innovation.
    Weilbaecher A
    Ann Health Law; 2009; 18(2):281-309, 7 p. preceding i. PubMed ID: 21950242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global pharmaceutical development and access: critical issues of ethics and equity.
    Lage A
    MEDICC Rev; 2011 Jul; 13(3):16-22. PubMed ID: 21778954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comment: compulsory licensing of patented pharmaceutical inventions: evaluating the options.
    Reichman JH
    J Law Med Ethics; 2009; 37(2):247-63. PubMed ID: 19493070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug patent protection: how long is long enough?
    Sibbald B
    CMAJ; 2001 May; 164(9):1331. PubMed ID: 11341146
    [No Abstract]   [Full Text] [Related]  

  • 9. Three reasons why a global market in pharmaceutical products is inherently unjust.
    Holm S
    J Soc Philos; 2000; 31(4):391-400. PubMed ID: 15069945
    [No Abstract]   [Full Text] [Related]  

  • 10. Access to medicines and the rhetoric of responsibility.
    Barry C; Raworth K
    Ethics Int Aff; 2002; 16(2):57-70. PubMed ID: 15709279
    [No Abstract]   [Full Text] [Related]  

  • 11. Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects.
    Bird RC
    J Law Med Ethics; 2009; 37(2):209-21. PubMed ID: 19493067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novartis challenges India's drug patent laws in Supreme Court.
    Billingsley M
    BMJ; 2012 Feb; 344():e1279. PubMed ID: 22354594
    [No Abstract]   [Full Text] [Related]  

  • 13. Developing medicines in line with global public health needs: the role of the World Health Organization.
    Pang T
    Camb Q Healthc Ethics; 2011 Apr; 20(2):290-7. PubMed ID: 21435304
    [No Abstract]   [Full Text] [Related]  

  • 14. Patent infringement.
    Kempton L
    Nat Rev Drug Discov; 2005 Feb; 4(2):97. PubMed ID: 15756754
    [No Abstract]   [Full Text] [Related]  

  • 15. The Health Impact Fund: a potential solution to inequity in global drug access.
    Banerjee A; Pogge T
    Indian J Med Ethics; 2010; 7(4):240-3. PubMed ID: 22106579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
    Higgins MJ; Graham SJ
    Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
    [No Abstract]   [Full Text] [Related]  

  • 17. Amendment to UK Patent Act provides further exception to patent infringement.
    Sklan A
    Pharm Pat Anal; 2014 Jul; 3(4):349. PubMed ID: 25291308
    [No Abstract]   [Full Text] [Related]  

  • 18. Should ANVISA be permitted to reject pharmaceutical patent applications in Brazil?
    Mueller LL; Taketsuma Costa SM
    Expert Opin Ther Pat; 2014 Jan; 24(1):1-4. PubMed ID: 24206261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research on the pharmaceutical intellectual property protection and supervision of pharmacy administration.
    Xu Z; Chen W
    Pak J Pharm Sci; 2017 May; 30(3(Special)):1081-1087. PubMed ID: 28671085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patent immorality?
    Bloche MG; Jungman ER
    Am J Bioeth; 2002; 2(3):48-9. PubMed ID: 12230859
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.